Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, announced an exclusive partnership with Stallergenes Greer, a global healthcare company specializing in allergen immunotherapy (AIT), for the development of a new connected drug delivery device and companion mobile app, the first of its kind, for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.
Non-adherence to an AIT schedule and premature discontinuation of treatment remains a challenge in AIT management. This innovative, easy-to-use connected device will improve dose compliance and adherence, thus optimizing patient treatment outcomes.
Patient support programs and the provision of digital tools that place the patient first underpin Aptar Pharma’s vision for the future of digital health and are a way of ensuring true patient centricity.
Partnership underlining Aptar Pharma’s progress in digital therapeutics
This partnership underlines Aptar Pharma’s progress in the field of digital therapeutics, with the development work being undertaken by its Digital Health Group, which provides a full turnkey solution that includes device and software development expertise. The product will leverage Aptar Pharma’s Cohero platform, which will be tailored specifically for this use.
“We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to improve further the treatment journey of patients who suffer from allergies,” said Sai Shankar, vice president, Global Digital Healthcare Systems, Aptar Pharma.
“This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise, personalized allergen immunotherapy options adapted to the individual needs and lifestyle of patients. Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders,” added Dominique Pezziardi, general manager France, Belgium & Luxembourg, Global Head of Pricing and Market Access, Stallergenes Greer.
The newly-developed connected device and mobile app, part of Aptar Pharma’s portfolio of digital healthcare solutions, should be available in France in 2022 and will be progressively rolled out in Stallergenes Greer’s markets.
Aptar Pharma’s future digital healthcare plans include expansion into therapeutic areas such as respiratory, pain, CNS, allergy, oncology, diabetes, and the evolution of its range of digital support tools.
